Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
Elizabeth Dudnik(Rabin Medical Center), Nir Peled(Tel Aviv University), Anna Belilovski Rozenblum(Tel Aviv University), Ahuva Grubstein(Rabin Medical Center), Ludmila Fridel(Rabin Medical Center), Tzippy Shochat(Rabin Medical Center), Alona Zer(Technion – Israel Institute of Technology), Elias Bshara(Tel Aviv University), Aaron M. Allen(Tel Aviv University), Smadar Geva(Tel Aviv University), Maya Ilouze(Rabin Medical Center), Ofer Rotem(Rabin Medical Center), Laila C. Roisman(Shaare Zedek Medical Center)
Cited by 75
Related Papers
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642